DASHR: a new database of small human non-coding RNAs

November 20, 2015

Description:  Small non-coding RNAs (sncRNAs) are highly abundant RNAs, typically <100 nucleotides long, that act as key regulators of diverse cellular processes. Although thousands of sncRNA genes are known to exist in the human genome, no single database provides searchable, unified annotation, and expression information for full sncRNA transcripts and mature RNA products derived from […]

Read the full article →

Regulus Announces Grant of Patents Covering Lead microRNA Therapeutics

November 12, 2015

LA JOLLA, Calif., Nov. 12, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted patents related to Regulus’ most advanced microRNA therapeutics, RG-101, the company’s wholly-owned, GalNAc-conjugated anti-miR-122 being developed to treat […]

Read the full article →

miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-201

November 12, 2015

BOULDER, Colorado, – November 12, 2015 – miRagen Therapeutics, Inc. a biopharmaceutical company developing innovative microRNA-based therapeutics, today announced that it has initiated a Phase 1 clinical study of MRG-201, a synthetic microRNA mimic (promiR) to microRNA-29b.  The Phase 1 trial is being conducted in normal healthy volunteers and may be extended to patients suffering from cutaneous […]

Read the full article →

RG-101 Update: Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK

November 3, 2015

Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients LA JOLLA, Calif., Nov. 3, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded development of RG-101, Regulus’ wholly-owned, […]

Read the full article →

New standard for miRNA annotations published in Annual Reviews of Genetics

November 2, 2015

MicroRNAs (miRNAs) are a novel class of gene regulators that are now the center of their own research field in human cancer: the non-coding RNA field. MiRNAs are ~22nt long non-coding RNA transcripts that derive from hairpin precursors and regulate gene-expression of target genes by inhibiting the protein production of the target genes’ messenger RNA […]

Read the full article →

Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis

October 28, 2015

LA JOLLA, Calif., Oct. 28, 2015 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple […]

Read the full article →

Abcam Webinar: Developing Durable miRNA Biomarker Technologies for Microbial Carcinogenesis in Resource Poor Settings

October 28, 2015

Abcam is hosting a free webinar titled “Developing durable miRNA biomarker technologies for microbial carcinogenesis in resource poor settings”. Live Webinar Details Wednesday, November 4, 2015 16:00-17:00 CET/ 15:00-16:00 GMT/ 10:00-11:00 EST/ 07:00-08:00 PST Register here: http://www.abcam.com/mirnaprofilingwebinar Webinar Summary: Currently, more than half of the global cancer burden occurs in low-and middle-income countries, with 40% […]

Read the full article →

15 Novel Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma, Serum and Urine

September 29, 2015

THOROLD, ON, Sept. 28, 2015 /PRNewswire/ – Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 15 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA […]

Read the full article →

Call for Papers: Special Issue – MicroRNA Regulation

September 28, 2015

The International Journal of Molecular Sciences (Impact Factor 2.862) is working on a Special Issue ” MicroRNA Regulation” and is calling for submissions. Deadline for manuscript submissions is 31 March 2016. For more information please read the letter of the special issue editor: Dear Colleagues, MicroRNA is a short non-coding RNA whose primary function is […]

Read the full article →

MicroRNA Prediction and Validation In Order to Understand Racial Health Disparities in Prostate Cancer

July 15, 2015

It is well documented that African American (AA) men have higher incidence and mortality in cancers of the prostate. Additionally, these cancers tend to be more aggressive when compared with European American (EA) men. Investigators at George Washington University, Duke University, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute […]

Read the full article →